Treatment planning of dose escalation for anal cancer in the PLATO trial

Treatment planning of dose escalation for anal cancer in the PLATO trial

Bibliografski detalji
Glavni autori:	Abbott, N, Christophides, D, Robinson, M, Copeland, J, Adams, R, Harrison, M, Hawkins, M, Muirhead, R, Sebag-Montefiore, D
Format:	Conference item
Izdano:	Elsevier 2017

Slični predmeti

Personalized dose escalation in anal cancer
od: Robinson, M, i dr.
Izdano: (2016)

A novel pretrial contouring exercise for the UK led PersonaLising Anal cancer radioTherapy dOse (PLATO) trial
od: Robinson, M, i dr.
Izdano: (2017)

Toxicity, tolerability & compliance of concurrent capecitabine or 5-fluorouracil in the radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort
od: Jones, C, i dr.
Izdano: (2018)

Initial results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015
od: Muirhead, R, i dr.
Izdano: (2016)

Stepwise multicenter introduction of intensity modulated radiation therapy for anal cancer in the United Kingdom: From consensus guidance to large-scale prospective audit, prior to future clinical trials
od: Gilbert, D, i dr.
Izdano: (2016)

The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus
od: Sebag-Montefiore, D, i dr.
Izdano: (2016)

Optimising RT dose for anal cancer - the development of three clinical trials in one platform
od: Sebag-Montefiore, D, i dr.
Izdano: (2017)

Early stage anal margin cancer: towards evidence‐based management
od: Renehan, A, i dr.
Izdano: (2019)

A tumor control probability model for anal squamous cell carcinoma
od: Muirhead, R, i dr.
Izdano: (2015)

Radiation treatment planning with embedded dose escalation
od: William T. Hrinivich, i dr.
Izdano: (2019-08-01)

Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT)
od: Durrant, L, i dr.
Izdano: (2016)

Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma
od: Shakir, R, i dr.
Izdano: (2019)

Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer
od: Robinson, M, i dr.
Izdano: (2015)

Analysis of on-trial quality assurance for the SPARC clinical trial using novel peer-review methodology
od: Holyoake, D, i dr.
Izdano: (2018)

Normal tissue doses during isotoxically dose escalated lung radiation therapy using MR-linacs
od: Bendall, L, i dr.
Izdano: (2018)

Robust dose planning objectives for mesorectal radiotherapy of early stage rectal cancer – A multicentre dose planning study
od: Ane L. Appelt, i dr.
Izdano: (2019-09-01)

Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer.
od: Warren, S, i dr.
Izdano: (2014)

Dose escalation of a curcuminoid formulation
od: Crowell James, i dr.
Izdano: (2006-03-01)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
od: Robinson, M, i dr.
Izdano: (2019)

Dose Escalation Trial of Desulfated Heparin (ODSH) in Septic Peritonitis
od: Katie D. Mauro, i dr.
Izdano: (2022-04-01)

Isotoxic dose escalation with real-time imaging on an MR-linac in lung radiation therapy
od: Bendall, L, i dr.
Izdano: (2018)

Plato /
od: 266104 Hare, R. M., i dr.
Izdano: (1992)

Changes in pelvic active bone marrow seen on FDG-PET in patients receiving concurrent chemoradiation for anal cancer
od: Robinson, M, i dr.
Izdano: (2018)

Prognostic factors for patients with anal cancer treated with conformal radiotherapy—a systematic review
od: Stelios Theophanous, i dr.
Izdano: (2022-06-01)

CHARIOT: Our first dose escalation trial using the time to event continual reassessment method – design, difficulties, delivery
od: Frangou, E, i dr.
Izdano: (2018)

Is there a role for a biological boost in squamous cell anal cancer?
od: Sabbagh, A, i dr.
Izdano: (2018)

The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation
od: Carrington, R, i dr.
Izdano: (2015)

The role of biological dose-escalation for pancreatic cancer
od: Anna M.E. Bruynzeel, i dr.
Izdano: (2019-09-01)

Is there a role for an FDG derived biological boost in squamous cell anal cancer?
od: Sabbagh, A, i dr.
Izdano: (2018)

Planning for pleasure: Plato on hedonist prudentialism
od: O'Reilly, KR
Izdano: (2019)

The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation
od: Warren, S, i dr.
Izdano: (2015)

Modulation of myocardial creatine transporter levels and the effects of gene regulation and post-translational modification on its function
od: Sebag-Montefiore, L
Izdano: (2012)

Clinical and dosimetric factors impacting radiation pneumonitis in isotoxically dose-escalated NSCLC
od: Vivekanandan, S, i dr.
Izdano: (2017)

Is there a role for an 18F-fluorodeoxyglucose-derived biological boost in squamous cell anal cancer?
od: Sabbagh, A, i dr.
Izdano: (2018)

Dose escalation pre-clinical trial of novel DOK7-AAV in mouse model of DOK7 congenital myasthenia
od: Cossins, J, i dr.
Izdano: (2025)

Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study.
od: Guerrero Urbano, T, i dr.
Izdano: (2010)

Patient-reported outcomes in PROSPECT trial (Alliance N1048) – FOLFOX is not a panacea
od: Sean M. O'Cathail, i dr.
Izdano: (2023-11-01)

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
od: Fillekes, Q, i dr.
Izdano: (2013)

Critical theory since plato /
od: Adams, Hazard, i dr.
Izdano: (2005)

Plato’s Parmenides in Plato’s Sophist
od: David Horan
Izdano: (2019-05-01)